If you or a loved one has been diagnosed with non-muscle-invasive bladder cancer, your urologist has likely discussed BCG treatment for bladder cancer as a key part of the treatment plan. BCG (Bacillus Calmette-Guerin) treatment for bladder cancer is a form of immunotherapy that has been the gold standard for preventing recurrence and progression of early-stage bladder cancer for over four decades.
BCG is a live, weakened form of the bacterium Mycobacterium bovis, originally developed as a tuberculosis vaccine. When instilled directly into the bladder, it triggers a powerful immune response that targets and destroys residual cancer cells. The NIH considers BCG the most effective intravesical therapy available for non-muscle-invasive bladder cancer, with proven ability to reduce both recurrence and progression to more advanced disease. For a broader understanding of bladder cancer, including early warning signs, read our article on symptoms of bladder cancer. You can also explore our conditions guide for more on related conditions.
How BCG Treatment Works
BCG immunotherapy works differently from chemotherapy. Rather than directly killing cancer cells, BCG stimulates your own immune system to recognize and attack them. Here is how the process works at a biological level:
- BCG bacteria attach to the bladder wall: After being instilled into the bladder through a catheter, the BCG bacteria bind to the urothelial lining, particularly in areas where cancer cells are present or where tissue has been disrupted by surgery.
- Immune cells are recruited: The presence of foreign bacteria triggers an immune response. White blood cells, including T cells, natural killer cells, and macrophages, flood into the bladder wall.
- Cancer cells are targeted: The activated immune cells attack both the BCG bacteria and the nearby cancer cells. Research published in PubMed shows that BCG creates a localized inflammatory environment that is hostile to tumor survival.
- Immune memory develops: Over the course of treatment, the immune system develops a sustained response against bladder cancer cells, providing ongoing protection against recurrence.
This immune-mediated mechanism is why BCG is classified as immunotherapy and why it remains effective even decades after its first use in bladder cancer treatment in 1976.
Who Is a Candidate for BCG Treatment?
BCG treatment is recommended for specific stages and grades of bladder cancer. According to the American Urological Association (AUA) guidelines, BCG is indicated for:
- High-grade non-muscle-invasive bladder cancer (NMIBC): Including Ta high-grade and T1 tumors
- Carcinoma in situ (CIS): A flat, high-grade cancer that lines the bladder surface. BCG is considered the primary treatment for CIS.
- Intermediate-risk NMIBC: In patients with recurrent or multiple low-grade tumors, BCG may be recommended as an alternative to intravesical chemotherapy.
BCG is not appropriate for muscle-invasive bladder cancer (T2 and beyond), which typically requires more aggressive treatment such as radical cystectomy, systemic chemotherapy, or radiation. It is also generally not used for single, small, low-grade Ta tumors, which have a low risk of progression.
What to Expect During BCG Treatment
Understanding the treatment protocol can help ease anxiety about the process. BCG treatment for bladder cancer is administered in two phases:
Induction Phase
The induction course consists of 6 weekly instillations, typically beginning 2 to 4 weeks after the transurethral resection of bladder tumor (TURBT) surgery. Each treatment session follows a similar pattern:
- A thin catheter is inserted into the bladder through the urethra.
- The BCG solution is slowly instilled into the bladder through the catheter.
- The catheter is removed.
- You are asked to hold the solution in your bladder for approximately 2 hours, changing positions periodically to ensure the solution contacts all surfaces of the bladder.
- After 2 hours, you urinate to expel the solution.
The entire in-office procedure takes about 15 to 20 minutes, not including the 2-hour retention period. Most patients can resume normal activities the same day, though some experience fatigue or urinary symptoms afterward.
Maintenance Phase
After completing induction, maintenance BCG is critical for long-term cancer control. The most widely used maintenance schedule, developed by the Southwest Oncology Group (SWOG), consists of 3 weekly BCG instillations at 3 months, 6 months, and then every 6 months for up to 3 years.
According to the Mayo Clinic, maintenance BCG significantly reduces the risk of recurrence compared to induction alone. Studies published in PubMed show that the combination of induction plus maintenance BCG reduces the risk of tumor recurrence by approximately 30 to 40 percent and the risk of progression by 27 percent compared to TURBT alone.
Side Effects of BCG Treatment
Because BCG involves instilling live bacteria into the bladder, side effects are common and are actually a sign that the immune system is responding. Most side effects are temporary and manageable:
Common Side Effects (Affecting Most Patients)
- Urinary frequency and urgency: The need to urinate more often and with greater urgency, typically lasting 24 to 48 hours after each treatment
- Dysuria: Burning or discomfort during urination
- Hematuria: Blood in the urine, which may appear pink or red
- Flu-like symptoms: Low-grade fever, chills, fatigue, and body aches lasting 24 to 72 hours
- Bladder irritation: General discomfort in the lower abdomen
Less Common but Serious Side Effects
- BCG infection (BCGosis): In rare cases (less than 5 percent), BCG bacteria can spread beyond the bladder, causing systemic infection. Symptoms include high fever (above 101.3 degrees Fahrenheit) lasting more than 48 hours, severe malaise, and signs of infection in other organs. This requires immediate medical treatment with anti-tuberculosis medications.
- Granulomatous prostatitis: BCG can cause inflammation in the prostate gland in men.
- Allergic reactions: Rash, joint pain, or other allergic-type reactions can occur.
- Bladder contracture: Chronic BCG treatment can occasionally lead to a decrease in bladder capacity over time.
The Cleveland Clinic advises patients to contact their doctor if they experience fever above 101.3 degrees Fahrenheit lasting longer than 48 hours, severe pain, or inability to urinate after BCG treatment.
Success Rates and Effectiveness
BCG remains one of the most effective treatments for non-muscle-invasive bladder cancer. Research data from the NIH and PubMed shows:
- Complete response rate for CIS: Approximately 70 to 75 percent of patients with carcinoma in situ achieve a complete response after BCG induction.
- Recurrence reduction: BCG with maintenance reduces 5-year recurrence rates by approximately 30 to 40 percent compared to TURBT alone.
- Progression reduction: BCG reduces the risk of progression to muscle-invasive disease by approximately 27 percent.
- Long-term outcomes: With appropriate maintenance therapy, many patients remain disease-free for years.
However, approximately 30 to 40 percent of patients will experience recurrence despite BCG treatment, and about 10 to 15 percent will develop BCG-unresponsive disease. For these patients, alternative treatments including second-line immunotherapies, intravesical chemotherapy, or radical cystectomy may be considered.
Important Precautions During BCG Treatment
Because BCG contains live bacteria, several precautions are necessary:
- Avoid immunosuppressive medications: Drugs that weaken the immune system can reduce BCG effectiveness and increase the risk of systemic BCG infection.
- Disinfect the toilet: After urinating out the BCG solution, add 2 cups of undiluted bleach to the toilet, let it sit for 15 to 20 minutes before flushing, and clean the toilet seat.
- Hydrate well: Drink plenty of fluids after treatment to flush the bladder.
- Avoid sexual contact: Refrain from sexual activity for 48 hours after each treatment to prevent potential transmission of BCG bacteria to a partner.
- Report symptoms promptly: Persistent high fever, severe urinary symptoms, or signs of systemic illness should be reported to your medical team immediately.
- Do not receive BCG during active UTI: Treatment is typically postponed if you have an active urinary tract infection or if traumatic catheterization occurs.
Frequently Asked Questions
How painful is BCG treatment?
The catheter insertion may cause brief discomfort similar to the sensation of urinating, but the instillation of the BCG solution itself is generally painless. The most uncomfortable part for many patients is holding the solution in the bladder for 2 hours, as it may cause urgency and bladder pressure. After the treatment, most patients experience mild burning with urination and increased frequency for 24 to 48 hours, which can be managed with over-the-counter pain medication and increased fluid intake.
Can BCG cure bladder cancer?
BCG can achieve long-term remission in many patients with non-muscle-invasive bladder cancer, and some patients remain disease-free indefinitely. However, because bladder cancer has a high recurrence rate, the term “cure” is used cautiously. The NIH emphasizes that ongoing surveillance with regular cystoscopies is essential even after a complete response to BCG, as recurrences can occur years later.
What happens if BCG treatment does not work?
If bladder cancer recurs or persists after adequate BCG therapy (known as BCG-unresponsive disease), several options are available. These include pembrolizumab (Keytruda), nadofaragene firadenovec (Adstiladrin) gene therapy, intravesical chemotherapy combinations, or radical cystectomy (surgical removal of the bladder). Your urologist and oncologist will discuss the options best suited to your specific situation.
Is BCG treatment the same as the BCG tuberculosis vaccine?
BCG treatment uses the same Mycobacterium bovis strain as the BCG tuberculosis vaccine, but the formulation and administration route are different. For bladder cancer, BCG is instilled directly into the bladder through a catheter rather than injected under the skin. The dose used for bladder cancer treatment is significantly higher than the vaccine dose. Because of this difference, receiving BCG for bladder cancer can cause a positive tuberculosis skin test (PPD) afterward.
Key Takeaway
BCG treatment for bladder cancer remains the most effective intravesical therapy for non-muscle-invasive bladder cancer, with decades of evidence supporting its ability to reduce recurrence and prevent progression to more advanced disease. While side effects are common, they are generally manageable and are a sign that the immune system is responding appropriately. Success depends on completing the full course of treatment, including maintenance therapy, and adhering to the recommended surveillance schedule. If you have been recommended BCG therapy, discuss any concerns with your urologist so you can approach treatment with confidence.